Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/formulation-characterization-and-stability-of-protein-drugs-case-histories-pharmaceutical-biotechnology-vol-9/pearlman/descriptif_1236165
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=1236165

Formulation, Characterization, and Stability of Protein Drugs, 2002 Case Histories Pharmaceutical Biotechnology Series, Vol. 9

Langue : Anglais

Coordonnateurs : Pearlman Rodney, Wang Y. John

Couverture de l’ouvrage Formulation, Characterization, and Stability of Protein Drugs
Leading scientists offer detailed profiles of ten protein drugs currently in development. The case histories of these important new compounds are described from the perspective of their formulation, characterization, and stability. This ready reference also features recent data and an abundance of previously unpublished information. The in-depth coverage includes a highly useful compendium of degradation sites occurring in over 70 proteins. An invaluable aid in the rapid identification of potential `hot spots' in proteins, this accessible compilation allows for inspection of the protein's primary structure and preparation of a hydroflex plot.
A Compendium and Hydropathy/Flexibility Analysis of Common Reactive Sites in Proteins: Reactivity at Asn, Asp, Gin and Met Motifs in Neutral pH Solution; M. Powell. Characterization, Stability, and Formulations of Basic Fibroblast Growth Factor; Y.J. Wang, et al. The Characterization, Stabilization, and Formulation of Acidic Fibroblast Growth Factor; D.B. Volkin, C.R. Middaugh. Stability, Characterization, Formulation, and Delivery System Development for Transforming Growth Factor-Beta1; W.R. Gombotz, et al. Stability and Characterization of Recombinant Human Relaxin; T.H. Nguyen, S.J. Shire. Interferon-£Ii£-1b (Betaserson): A Model for Hydrophobic Therapeutic Proteins; L.S. Lin, et al. Characterization, Formulation, and Stability of Neupogen (Filgrastim): A Recombinant Human Granulocyte Colony Stimulating Factor; A.C. Herman, et al. Development and Shelflife Determination of Recombinant Human Granulocytemacrophage Colonystimulating Factor (Leukin, GMCSF); J. Geigert, B.F.D. Ghrist. Formulation Development of an Antifibrin Monoclonal Antibody Radiopharmaceutical; M. Kamat, et al. Biophysical Characterization and Formulation of TP40: A Chimeric Protein which Requires a pHdependent Conformational Change for Its Biological Activity; G. Sanyal, et al. Stability Characterization and Formulation Development of Recombinant Human Deoxyribonuclease I [Pulmozyme, (Dornase Alpha)]; S.J. Shire. Index.
This book offers detailed profiles of ten protein drugs currently in development. The case histories of these important new compounds are described from the perspective of their formulation, characterization, and stability. This ready reference also features recent data and an abundance of previously unpublished information. The in-depth coverage includes a highly useful compendium of degradation sites occurring in over 70 proteins.

Date de parution :

Ouvrage de 432 p.

15.2x22.9 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 210,99 €

Ajouter au panier

Thème de Formulation, Characterization, and Stability of Protein... :